Carboxypeptidase A-1 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Carboxypeptidase A1 (CPA1, EC 3.4.17.1; UniProt P15085), expressed in HEK293 cells. For use in peptide cleavage assays, inhibitor profiling, and antibody validation against the matched Triple Point Biologics antibody (RP-CarboxypeptidaseA1).
Expression system
HEK293
Cat. #
REC-CarboxypeptidaseA1

In stock

SKU
REC-CarboxypeptidaseA1
$498.00

Target Overview

Carboxypeptidase A1 (CPA1; UniProt P15085) is a secreted zinc-dependent metallocarboxypeptidase that catalyses the stepwise removal of C-terminal amino acid residues from peptide substrates (EC 3.4.17.1). The enzyme demonstrates broad substrate tolerance across hydrophobic and neutral C-terminal residues, but exhibits little or no catalytic activity toward substrates terminating in Asp, Glu, Arg, Lys, or Pro. CPA1 also catalyses conversion of leukotriene C4 to leukotriene F4 through amide-bond hydrolysis, implicating it in lipid mediator metabolism beyond classical proteolytic function. The full-length human CPA1 precursor spans 419 amino acids and is processed to an active form upon secretion. This recombinant CPA1 is expressed in HEK293 cells, a mammalian system that supports appropriate glycosylation and folding of secreted proteases, yielding a form likely to reflect the native conformational and activity profile of the human enzyme. It is suitable for in-vitro enzymatic activity assays using synthetic chromogenic or fluorogenic peptide substrates, kinetic parameter (Km, kcat) determination, and small-molecule inhibitor screening by IC50 measurement. Researchers studying the structural basis of CPA1 substrate selectivity or the effect of point mutations associated with pancreatitis-linked CPA1 variants can use this recombinant as a well-characterised wild-type reference enzyme. Researchers requiring an antigen standard for antibody validation can pair this recombinant directly with the Triple Point Biologics matched antibody (RP-CarboxypeptidaseA1), which has been validated for Western blot against human CPA1. Using the recombinant and antibody together provides a defined positive-control antigen for titration experiments and specificity confirmation across experimental workflows.

Background

CPA1 is expressed predominantly in pancreatic acinar cells, where it is synthesised as an inactive zymogen (procarboxypeptidase A1) and secreted into the pancreatic duct for activation in the duodenum. Its primary physiological role is dietary protein digestion, operating downstream of endopeptidases such as trypsin and chymotrypsin to liberate individual amino acids from partially digested peptide chains. Beyond digestion, CPA1 participates in arachidonic acid metabolite processing, including leukotriene pathway modulation, making it of interest in inflammation-focused biochemical research. In the context of pancreatic disease research, CPA1 has attracted sustained interest as a genetic and biochemical study target. Loss-of-function or misfolding variants in CPA1 have been characterised in cohorts with hereditary and idiopathic chronic pancreatitis, where aberrant zymogen processing and endoplasmic reticulum stress are studied as mechanistic contributors to acinar cell injury. Tiosano et al. (2026, PMID: 41417682) characterised CPA1 variants in an Israeli acute recurrent pancreatitis cohort alongside electrophysiological and genetic analyses, illustrating the continued utility of genotype–function correlation studies in which a well-characterised recombinant enzyme serves as the wild-type enzymatic reference. In parallel, Inamdar et al. (2026, PMID: 41419303) investigated how hereditary chronic pancreatitis-associated plasticity cooperates with oncogenic signalling in early pancreatic carcinogenesis — a study context in which acinar enzyme identity, including CPA1, is central to defining cell-of-origin phenotypes. Beyond human pancreatic biology, carboxypeptidase A family members have been characterised in immune cell compartments in other species. Wu et al. (2026, PMID: 41771430) described the expression and function of a related CPA family member in zebrafish neutrophils and mast cells, reflecting broader interest in CPA-family enzymes as markers and functional contributors across immune cell types. This body of published research underscores the value of recombinant CPA1 as a reference reagent for enzymatic, structural, and translational studies — providing a reproducible, mammalian-expressed protein for in-vitro characterisation of substrate selectivity, inhibitor sensitivity, and structure–activity relationships in the carboxypeptidase field.

Applications

  • Chromogenic or fluorogenic peptide substrate cleavage activity assay (e.g., hippuryl-L-phenylalanine)
  • Kinetic parameter determination (Km, kcat, kcat/Km) for C-terminal amino acid substrates
  • Small-molecule inhibitor IC50 profiling and selectivity screening
  • Comparison of wild-type CPA1 activity against pancreatitis-associated variant enzymes
  • Antibody validation positive control paired with Triple Point Biologics RP-CarboxypeptidaseA1 (Western blot, IHC)
  • Leukotriene C4 amide-bond hydrolysis assay for lipid mediator metabolism studies
  • Substrate specificity profiling by LC-MS/MS using synthetic peptide libraries

References

  1. Wu Z et al. Expression and function of zebrafish carboxypeptidase A5 in neutrophils and mast cells. Fish Shellfish Immunol. 2026. doi:10.1016/j.fsi.2026.111239. PMID: 41771430
  2. Inamdar TV et al. Hereditary chronic pancreatitis induced plasticity cooperates with mutant Kras in early pancreatic carcinogenesis. Gut. 2026. doi:10.1136/gutjnl-2025-335947. PMID: 41419303
  3. Tiosano M et al. Genetic and Electrophysiological Characterization of Acute Recurrent Pancreatitis in Israeli Patients. Pancreas. 2026. doi:10.1097/MPA.0000000000002617. PMID: 41417682
  4. Zeng S et al. Construction and evaluation of a chimeric vaccine against Clostridium perfringens type a of sika deer. Vaccine. 2025. doi:10.1016/j.vaccine.2025.127899. PMID: 41161044
  5. Li J et al. Integrated transcriptomic and metabolomic analysis reveals key regulatory genes and pathways associated with feed conversion efficiency in Tianchang Sanhuang chicken. Poult Sci. 2025. doi:10.1016/j.psj.2025.105912. PMID: 41043385

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted (most); lysosome (some)

Frequently Asked Questions

What is the expected molecular weight of recombinant CPA1 on SDS-PAGE or Western blot?

The full-length human CPA1 precursor is 419 amino acids (~47 kDa predicted from sequence). Because this recombinant is expressed in HEK293 cells, N-linked glycosylation adds mass, so the apparent band on reducing SDS-PAGE typically runs between 50–55 kDa. The propeptide (~94 residues) may or may not be cleaved depending on the lot's processing state; check the Certificate of Analysis for the confirmed apparent MW of your specific lot. Purity is >95% by SDS-PAGE, so you should see a single predominant band with minimal higher-MW species.

Is the recombinant CPA1 supplied as the zymogen precursor or the processed active enzyme?

This product is supplied as an active enzyme form, not the full zymogen. The CPA1 precursor undergoes propeptide removal upon secretion; HEK293 expression recapitulates this secretion-coupled processing, yielding a form analogous to the mature secreted enzyme (approximately residues 95–419 of the UniProt P15085 canonical sequence). The active zinc-dependent metallocarboxypeptidase domain is intact and catalytically competent as supplied. If your experiment specifically requires the zymogen form, this product is not appropriate — contact us before ordering.

What substrates should I use to measure recombinant CPA1 carboxypeptidase activity in vitro?

The most widely used chromogenic substrate for CPA1 (EC 3.4.17.1) activity assays is hippuryl-L-phenylalanine (Hip-Phe), with absorbance monitored at 254 nm after hippuric acid release. Hippuryl-L-arginine is a useful negative-control substrate because CPA1 shows little activity toward C-terminal basic residues (Arg, Lys). Fluorogenic substrates such as Abz-Gly-Phe(NO2)-OH also work well for higher-sensitivity plate-based formats. Ensure your substrate solution is freshly prepared; carry the blank without enzyme to subtract non-enzymatic hydrolysis.

What buffer conditions are optimal for recombinant CPA1 activity assays?

CPA1 is a zinc-dependent metallocarboxypeptidase, so avoid chelating agents (EDTA, EGTA) entirely — they will strip the catalytic Zn²⁺ and abolish activity. The storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl₂) is compatible with most activity assays when diluted ≤1:10 into the reaction. Optimal pH is 7.5–8.0 for most hydrophobic C-terminal substrates. Including 0.01% BSA in the dilution buffer helps stabilize activity at low enzyme concentrations (<10 nM). Keep reactions at 37°C for physiological relevance.

What starting concentration of recombinant CPA1 should I use for a kinetic activity assay?

For initial Km/Vmax determination with Hip-Phe, a useful starting point is 5–20 nM CPA1 with substrate concentrations spanning 0.1–5 mM. At these enzyme concentrations the reaction should be linear for at least 10–15 minutes at 37°C. If signal is low, scale up to 50 nM; if background hydrolysis is masking the signal, reduce substrate concentration or drop enzyme to 2–5 nM. For inhibitor IC50 studies, titrate inhibitor against a fixed enzyme concentration producing ~20–30% substrate conversion at the assay endpoint to maintain sensitivity.

Can I use recombinant CPA1 as a positive control for Western blot with the matched RP-CarboxypeptidaseA1 antibody?

Yes — this is the primary intended cross-use case. The matched rabbit polyclonal antibody (SKU: RP-CarboxypeptidaseA1) was raised and validated in the same laboratory that produced this recombinant, so compatibility on Western blot is confirmed. Load 50–200 ng of recombinant CPA1 per lane alongside your cell lysate or tissue samples. The antibody detects the processed ~50–55 kDa HEK293-expressed band cleanly under denaturing conditions. This pairing is particularly useful when validating the antibody against low-expressing samples where an unambiguous positive control band is essential.

How much recombinant CPA1 should I load for a Western blot positive control lane?

100 ng per lane is a reliable starting point when using RP-CarboxypeptidaseA1 at a primary antibody dilution of 1:500–1:2000. If your detection system (ECL, fluorescent secondary) is highly sensitive, titrate down to 25–50 ng to avoid signal saturation that can obscure accurate band-size estimation. Boil the recombinant in 1× Laemmli buffer with β-mercaptoethanol for 5 minutes before loading — the glycosylated ~50–55 kDa band is fully detected under reducing SDS-PAGE conditions. Avoid loading >500 ng, as glycoprotein smearing can complicate comparison with endogenous bands.

How should I handle, dilute, and store recombinant CPA1 to preserve enzymatic activity?

The protein is shipped and stored at -20°C in single-use aliquots in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl₂. Do not refreeze after thawing — freeze-thaw cycling degrades activity. For working dilutions, use the storage buffer supplemented with 0.01% BSA to prevent adsorption to tube walls at low concentrations (<50 nM). Diluted enzyme on ice is stable for 4–6 hours; do not pre-dilute the day before. Unopened aliquots stored correctly are stable for 12 months from the date of receipt. Confirm activity with a Hip-Phe assay if the product has been stored for an extended period.

Validation imagery coming soon

Western blot validation figures for REC-CarboxypeptidaseA1 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →